JP7644006B2 - カルボラン化合物、カルボラン類似体、およびその使用方法 - Google Patents

カルボラン化合物、カルボラン類似体、およびその使用方法 Download PDF

Info

Publication number
JP7644006B2
JP7644006B2 JP2021531638A JP2021531638A JP7644006B2 JP 7644006 B2 JP7644006 B2 JP 7644006B2 JP 2021531638 A JP2021531638 A JP 2021531638A JP 2021531638 A JP2021531638 A JP 2021531638A JP 7644006 B2 JP7644006 B2 JP 7644006B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutical composition
alkyl
fibrotic condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510008A (ja
JP2022510008A5 (enExample
Inventor
チャールズ コス，クリストファー
ベネット，チャド
パトリック，ジェフリー
ワン，ダーシェン
Original Assignee
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ・ステイト・イノベーション・ファウンデーション filed Critical オハイオ・ステイト・イノベーション・ファウンデーション
Publication of JP2022510008A publication Critical patent/JP2022510008A/ja
Publication of JP2022510008A5 publication Critical patent/JP2022510008A5/ja
Application granted granted Critical
Publication of JP7644006B2 publication Critical patent/JP7644006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021531638A 2018-12-03 2019-12-03 カルボラン化合物、カルボラン類似体、およびその使用方法 Active JP7644006B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862774688P 2018-12-03 2018-12-03
US62/774,688 2018-12-03
US201962798713P 2019-01-30 2019-01-30
US201962798711P 2019-01-30 2019-01-30
US201962798710P 2019-01-30 2019-01-30
US62/798,711 2019-01-30
US62/798,710 2019-01-30
US62/798,713 2019-01-30
PCT/US2019/064228 WO2020117799A1 (en) 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022510008A JP2022510008A (ja) 2022-01-25
JP2022510008A5 JP2022510008A5 (enExample) 2022-12-08
JP7644006B2 true JP7644006B2 (ja) 2025-03-11

Family

ID=70974874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531638A Active JP7644006B2 (ja) 2018-12-03 2019-12-03 カルボラン化合物、カルボラン類似体、およびその使用方法

Country Status (7)

Country Link
US (2) US20220040210A1 (enExample)
EP (1) EP3890750A4 (enExample)
JP (1) JP7644006B2 (enExample)
CN (1) CN113347979B (enExample)
AU (1) AU2019393785A1 (enExample)
CA (1) CA3122029A1 (enExample)
WO (1) WO2020117799A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515580A (zh) * 2020-03-11 2022-12-23 俄亥俄州国家创新基金会 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法
WO2023239764A1 (en) * 2022-06-08 2023-12-14 Ohio State Innovation Foundation Methods and compositions for treating lupus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043016A1 (en) 1999-01-22 2000-07-27 Institute Of Medicinal Molecular Design. Inc. DICARBA-closo-DODECABORANE DERIVATIVES
WO2009021978A2 (de) 2007-08-13 2009-02-19 Universität Leipzig Carbaboranreste enthaltende verbindungen und deren verwendung in der medizin, insbesondere für die verwendung in der tumortherapie
JP2010208996A (ja) 2009-03-11 2010-09-24 Okayama Univ 置換フェニルプロピオン酸誘導体を含有する医薬組成物
US20140303390A1 (en) 2011-10-24 2014-10-09 Univerzita Palackeho V Olomouci Carbonic anhydrase inhibitors and method of their production
JP2018533621A (ja) 2015-09-17 2018-11-15 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100884489B1 (ko) * 2007-02-21 2009-02-18 원광대학교산학협력단 1,3,5-트리아진-4-일-디카르보-클로소-도데카보란 유도체,이의 제조방법 및 이를 포함하는 약학적 조성물
ES2700141T3 (es) * 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043016A1 (en) 1999-01-22 2000-07-27 Institute Of Medicinal Molecular Design. Inc. DICARBA-closo-DODECABORANE DERIVATIVES
WO2009021978A2 (de) 2007-08-13 2009-02-19 Universität Leipzig Carbaboranreste enthaltende verbindungen und deren verwendung in der medizin, insbesondere für die verwendung in der tumortherapie
JP2010208996A (ja) 2009-03-11 2010-09-24 Okayama Univ 置換フェニルプロピオン酸誘導体を含有する医薬組成物
US20140303390A1 (en) 2011-10-24 2014-10-09 Univerzita Palackeho V Olomouci Carbonic anhydrase inhibitors and method of their production
JP2018533621A (ja) 2015-09-17 2018-11-15 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Experimental Biology and Medicine，2017年，242，pp.606-616
Inorg. Chem. ，2017年，56，pp.5510-5513
Molecular and Cellular Endocrinology，2016年，434，pp.57-68

Also Published As

Publication number Publication date
WO2020117799A1 (en) 2020-06-11
CN113347979B (zh) 2024-08-16
CN113347979A (zh) 2021-09-03
EP3890750A4 (en) 2022-08-10
AU2019393785A1 (en) 2021-06-17
AU2019393785A2 (en) 2021-06-24
US20250281515A1 (en) 2025-09-11
JP2022510008A (ja) 2022-01-25
CA3122029A1 (en) 2020-06-11
US20220040210A1 (en) 2022-02-10
EP3890750A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US11771712B2 (en) Carborane compounds and methods of use thereof
US20250281515A1 (en) Carborane compounds, carborane analogs, and methods of use thereof
US9783513B2 (en) STAT3 inhibitors and their anticancer use
CA2854836C (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
CN113429387B (zh) 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
WO2013006734A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
WO2013019690A1 (en) Small molecule inhibitors of il-6 and uses thereof
WO2023086365A1 (en) Compositions comprising amino lipid compounds and methods of making and use thereof
CN118891043A (zh) 包含脂质化合物的组合物以及制备和使用其的方法
HK40053312A (en) Carborane compounds, carborane analogs, and methods of use thereof
HK40053312B (zh) 碳硼烷化合物、碳硼烷类似物及其使用方法
US20250188098A1 (en) Carborane compounds and methods of use thereof
CN107207407A (zh) 用于治疗疾病和病症的组合物和方法
HK1261921B (en) Carborane compounds and methods of use thereof
HK1261921A1 (en) Carborane compounds and methods of use thereof
WO2023203185A1 (en) Mitochondriotropic benzamide potassium channel k v1.3 inhibitors
HK40113159A (zh) 包含氨基脂质化合物的组合物以及制备和使用其的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240821

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250227

R150 Certificate of patent or registration of utility model

Ref document number: 7644006

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150